The penetration of cefoperazone and moxalactam into pleural fluid was studied in 11 patients after intravenous infusion of 2-g doses of these agents. Clearance of these agents from pleural fluid was studied in seven patients after instillation of 1-g doses into the pleural space. The concentrations in pleural fluid after intravenous infusion of 2-g doses reached a peak of 7 to 25 ,ug/ml for cefoperazone and 9 to 35 ,ug/ml for moxalactam at 4 to 6 h after administration. These levels exceeded reported MICs for most susceptible organisms. The elimination half-life of both agents was about two to five times longer in pleural fluid than in serum. These prolonged elimination rates of both agents might be of great advantage for killing bacteria in the pleural space.
Although there have been numerous studies on the pharmacology of cefoperazone and moxalactam, little attention has been given to the distribution of these antimicrobial agents in pleural fluid. Believing that this could be important where infectious processes are involved, we have studied the penetration and clearance of both agents in pleural fluid.
MATERIALS AND METHODS
From May 1982 to November 1983, a total of 13 patients (10 men, 3 women; average age, 65 years; body weight, 43 to 65 kg) with pleural fluid participated in the study after informed consent was obtained. All subjects had normal renal and liver functions. Seven patients (patients 5, 6, 9, 10, 11, 12, and 13) had cytologically proven carcinomatous pleural effusion, and four patients (patients 2, 4, 7, and 8) had tuberculous pleural effusion that was confirmed with biopsy specimens of pleura showing the caseating epithelioid granulomas. Two other patients had empyema caused by mixed infections ofBacteroidesfragilis and Peptostreptococcus sp. (patient 3) and microaerophilic streptococci (patient 1). Each subject had 360 to 2,300 ml of pleural fluid containing 3.0 to 6.8 g of protein per dl at the time of testing. Except for that associated with empyema, pleural fluid was always sterile.
Two grams of cefoperazone was infused intravenously over 60 min in six patients, and 1 g of cefoperazone was instilled directly into the thoracic cavity in four patients. Similar doses of moxalactam were given intravenously in five patients and intrathoracically in three patients. Five patients (patients 7, 8, 9, 10, and 11) received both infusions and instillations. In these patients, the intravenous infusion was carried out first, the thoracic 3 to 14 days later. These intervals were long enough for the intravenously infused agents to disappear from pleural fluid.
Each subject had a thoracic catheter (Trocar catheter, size 10-12F) implanted before study, the exposed end of which was always clamped except during the time required for sampling. Just before drug administration, 10 to 20 ml of pleural fluid was obtained. Venous blood (5 to 10 ml) and pleural fluid (10 to 20 ml) were obtained at 0.1, 2, 4, 6, 12, and 24 h after initiation of drug administration. Pleural fluid * Corresponding author.
was drained off completely after the last sampling for estimation of total fluid volume. All samples were centrifuged, and serum and pleural fluid supernatants were stored at -20°C until being assayed. The agar diffusion method was used as bioassay. Serum samples were diluted with standard human serum, and pleural fluid was diluted with 20 M phosphate buffer (pH 7.0). Bacillus subtilis ATCC 6633 and Escherichia coli 3437 were used as the test organisms.
The half-life in serum and pleural fluid was calculated over the period extending from the time at peak concentration to the last sampling time (12 or 24 h).
RESULTS
Concentrations in serum and pleural fluid. Two-gram doses of cefoperazone were infused intravenously in six patients. The concentrations of cefoperazone in serum were 108 to 260 ,ug/ml at the end of infusion, 54 to 256 ,ug/ml at 2 h, and 29 to 70 ,ug/ml at 6 h. At 12 h, concentrations of 10 to 40 jig of cefoperazone per ml were present in five patients. Concentrations of cefoperazone in pleural fluid reached levels of 6 to 25 ,ug/ml in 4 to 6 h and decreased to 4 to 10 j,g/ml at 12 h (Table 1) .
Five patients received intravenous infusions of 2 g of moxalactam. Concentrations in serum ranged from 43 to 122 ,ug/ml at the end of infusion, 28 to 75 p.g/ml at 2 h, 10 to 33 ,ug/ml at 6 h, and, in three patients, 4 to 9 pug/ml at 12 h, below the level of detection in the other two patients.
Concentrations in pleural fluid were 9 to 35 jig/ml at 4 to 6 h and 4 to 19 ,ug/ml at 12 h (Table 1) .
One-gram doses of cefoperazone or moxalactam were instilled into the thoracic cavity of four and three patients, respectively. The initial concentrations in serum ranged from 350 to 6,800 ,ug of cefoperazone per ml and 315 to 4,980 ,ug of moxalactam per ml, depending on the volume of pleural fluid. At 24 h, the concentration of cefoperazone ranged from 28 to 640 ,ug/ml, and that of moxalactam ranged from 12 to 920 ,ug/ml. Concentrations of 8 to 35 jig of cefoperazone per ml and 3 to 9 ,ug of moxalactam per ml were present in serum at 2 to 6 h ( Table 2) .
The maximal levels of these agents in pleural fluid after intravenous infusions were not correlated with either protein content or total volume of pleural fluid. Furthermore, the ANTIMICROB. AGENTS CHEMOTHER. highest concentration (25 ,ug/ml for cefoperazone) was found levels of both agents exceeded reported MICs for most in the largest volume of pleural fluid (1,500 ml; patient 6), susceptible organisms (7, 9, 12, 13, 19) . In this study, we also and the subject with the largest volume of pleural fluid (1, 800 demonstrated that the half-lives of both agents in pleural ml) had the highest concentration (35 ,ug/ml for moxalactam;
fluid were about two to five times longer than in serum. patient 10).
The extravascular concentration of an antimicrobial agent Elimination half-life. Elimination rates of cefoperazone is thought to be dependent on a number of factors. First and moxalactam in serum and pleural fluid were calculated among these is protein binding, it being contended that high after both infusion and instillation. After infusion, the halfserum binding inhibits the distribution of drug into tissue life of cefoperazone in serum was 2.3 to 3.6 h, and that of fluid (8, 17) . We did not measure binding to pleural fluid moxalactam was 1.7 to 3.0 h. The half-life in pleural fluid protein of these agents, but previous investigators have was 5.9 to 9.4 h and 6.7 to 9.1 h for cefoperazone and demonstrated that cefoperazone has a binding to serum moxalactam, respectively. The elimination half-lives of both protein of 90%, compared with 53% for moxalactam (2, 14) .
agents were about two to five times longer in pleural fluid Extensive binding to serum protein notwithstanding, conthan in serum (Table 1) Table 2) . studied the concentrations of cephalosporins in the ascitic fluid of dogs with inferior vena cava ligation. They suggested that the appreciable binding of cephalosporins to ascitic fluid DISCUSSION protein serves to explain why total concentrations of these Although several investigators have studied the penetradrugs in ascitic fluid may be quite high. Therefore, binding of tion of older cephalosporins into pleural fluid (1, 6, 10, 11, cefoperazone and moxalactam to pleural fluid protein as well 15), we are not aware of any study of the distribution of as to serum protein seems to be important to limit the cefoperazone and moxalactam. When 2 g of cefoperazone or penetration into pleural fluid. moxalactam was administered intraveneously, the concenSecond, the presence of pleural inflammation might intrations of these agents in pleural fluid was 6 to 25 jig/ml for crease drug penetration into pleural fluid. The characteriscefoperazone and 9 to 35 ,ug/ml for moxalactam. These tics of pleural fluid in our patients suggest the presence of acute severe inflammation in pleural space, even though cell counts were not carried out. Third, Gerding et al. (4) have reported that the levels of antibiotic in ascitic fluid of dogs are related inversely to the volume of ascitic fluid. The large volumes of extravascular fluid, i.e., 4 to 6 liters, could have disturbed circulation and drug kinetics, which might inhibit drug penetration into extravascular fluid. In our study, however, pleural concentrations of both agents did not relate inversely to the volume of pleural fluid, the highest concentrations of both agents being found in subjects with the largest volumes of pleural fluid. These results may be mainly attributed to the smaller fluid volumes, which ranged from 0.4 to 2.3 liters in patients weighing 43 to 65 kg, compared with volumes of 4 to 10 liters in dogs weighing 18 to 22 kg. Van Etta et al. (16) have reported that the greater the surface area in relation to the volume of the extravascular space, the higher the absolute peak concentration of drug achieved in the extravascular space. Hence, the increase of pleural fluid volume in our study may be related to the increase of inflammatory pleural surface and, especially, the increase of the surface area in relation to the volume of pleural fluid.
The elimination rates of newer compounds in pleural fluid were one-half to one-fifth of those in serum. In general, our data support the results of Gerding et al. (3), who reported that the half-life of cefazolin, cephaloridine, cephapirin, and cephalothin in interstitial body fluid was 3.5 to 6.5 times those in serum. The prolonged elimination rates of cefoperazone and moxalactam in pleural fluid might be of great advantage for killing bacteria in the pleural cavity.
